Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)
NCT ID: NCT00564811
Last Updated: 2015-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2003-03-31
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients
NCT01750515
Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy
NCT02215525
Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
NCT01292161
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
NCT03402165
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
NCT01018615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
G1
No interventions assigned to this group
G2
Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)
Agaricus blazei powder, 10 grams/day, for 5 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)
Agaricus blazei powder, 10 grams/day, for 5 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Initiating the anti-viral treatment (interferon or pegylated interferon associate the ribavirin)
* Age: 24-70 years
* Gender :both the gender
* Race : all races
* To present serology positive to the anti-VHC ELISA
* To present genotype type 1,2,or 3
* Body mass index- \>18,5 e \< 35kg /m2
* Conditions full to the ORAL ingestion
Exclusion Criteria
* Restriction for oral ingestion
* The existence of surface of antigen of the hepatitis B virus(Ag HBs)
* The existence of antibody for the human immunodeficiency virus
* To be enclosed in another project of research or form of treatment
* Pregnant women
* Suckles
* Cirrhosis
* Patients with hepatitis auto-imune.
24 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UPECLIN HC FM Botucatu Unesp
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Caramori A Carlos, MD, PhD
Role: STUDY_CHAIR
Botucatu Medicine School - Sao Paulo State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal Medicine Department, Botucatu School of Medicine, São Paulo State University - UNESP
Botucatu, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
upeclin/HC/FMB-Unesp-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.